A lutein chewable tablet for ophthalmic use and its preparation method
By using fluidized bed spray granulation technology that combines oryzanol with poloxamer 188, the problems of lutein's solubility and stability during storage have been solved, achieving efficient solubilization and stability of lutein chewable tablets, making them suitable for industrial production.
Patent Information
- Application Number
- CN202611619574.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing technologies struggle to maintain the chemical stability of lutein while ensuring its solubility, especially in the presence of light, heat, and oxygen, where lutein preparations are prone to oxidative degradation during storage. Furthermore, existing solubilization methods have failed to effectively address the issue of its poor water solubility.
Using a compound carrier system of oryzanol and poloxamer 188, lutein, oryzanol and poloxamer 188 are dissolved together in anhydrous ethanol or 95% ethanol, and uniform drug-containing particles are formed by one-step spray granulation in a fluidized bed. This forms an antioxidant protective microenvironment and provides a hydrophilic release channel. Combined with the control of particle size and tablet hardness, solubilization and stabilization are integrated.
This technology achieves high dissolution and stability of lutein chewable tablets during storage, reduces production costs, improves product storage stability and patient compliance, and is suitable for industrial production.
Smart Images

Figure CN123101480A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of pharmaceutical preparation technology, specifically relating to a lutein chewable tablet for ophthalmic use, and a preparation method that is easy to implement industrially. Background Technology
[0002] Lutein (CAS No. 127-40-2) is an oxygen-containing carotenoid widely found in nature, belonging to the tetraterpenoid class of compounds. Its molecular structure consists of two six-membered rings and a polyene chain containing nine conjugated double bonds. Lutein effectively quenches singlet oxygen, scavenge free radicals, and absorbs blue light, playing a crucial role in maintaining normal retinal function. Numerous clinical studies have confirmed that lutein supplementation can significantly increase macular pigment optical density (MPOD) and serum lutein concentration, thereby reducing the risk of age-related macular degeneration (AMD). Age-related eye disease (AREDS) studies have shown that replacing β-carotene with lutein / zeaxanthin in AREDS-reducing formulations can lower the risk of progression to advanced AMD within 5 years by approximately 18%, without adverse effects on lung cancer risk. Based on this evidence-based medicine, lutein has been widely used in ophthalmic health supplements and pharmaceuticals.
[0003] However, lutein itself has significant defects in its physicochemical properties, severely restricting its formulation development and clinical application. Firstly, lutein has extremely poor water solubility. Its long conjugated double bond structure makes it highly lipophilic, resulting in poor water solubility and low oral bioavailability. Secondly, lutein has poor chemical stability. Lutein is highly sensitive to light, heat, oxygen, and acid-base environments. Heat treatment can cause lutein isomerization reactions, generating 9-cis and 13-cis lutein, which are prone to oxidative degradation during processing and storage. Thirdly, lutein faces many difficulties in formulation processing. Current conventional techniques for preparing lutein formulations still require further research to improve its bioavailability and reduce the degradation of related substances to minimize clinical side effects.
[0004] To address the aforementioned issues, those skilled in the art have conducted research in various directions. For example, patent CN103083270B discloses a lutein chewable tablet formulation, which includes lutein powder, xylitol, vitamin C, maltitol, maltodextrin, soluble dietary fiber, orange flavor, aspartame, magnesium stearate, and other ingredients. The tablets are produced through processes such as pulverization, mixing, granulation, drying, and compression. However, this method, using conventional formulation techniques, does not adequately consider the stability of lutein, which is highly susceptible to degradation under normal humid and hot conditions. It also fails to consider the solubilization requirements of lutein; no solubilization strategy is introduced, and the dissolution behavior of lutein is not examined or characterized. Consequently, the resulting chewable tablets fail to fully release lutein during actual consumption, and the bioavailability problem remains unresolved.
[0005] To address the shortcomings of lutein's poor water solubility and stability, patent CN117016785A discloses a functional lutein chewable tablet and its preparation method. The tablet comprises 10-20 parts lutein, 3-5 parts emulsifier, 30-50 parts vegetable oil, 50-60 parts filler, 2-4 parts steviol glycosides, 3-5 parts sodium carboxymethyl starch, and 2-4 parts magnesium stearate. The emulsifier consists of octenyl succinate starch ester, sodium stearoyl lactylate, and glyceryl citrate. However, the core strategy of this method is to prepare lutein as an oil-phase emulsion. The process involves emulsification and homogenization steps, resulting in a long process chain, high production costs, and the emulsion stability is affected by batch-to-batch quality of materials. Therefore, the industrial production of the product lacks process assurance regarding uniformity and reproducibility.
[0006] In 2023, Peng Liu et al. published "Improvements of Solubility and Bioavailability of Lutein Through Grafting with Hydrophilic Polyacrylic Acid" in the Journal of Pharmaceutical Sciences. This technology provides a strategy for modifying lutein. However, the technology involves esterification, requires the use of organic solvents and chemical reagents, and the product needs to be separated and purified. The process involves many steps and is costly. The final product is a nano-aqueous dispersion system in liquid form, which cannot be directly used for the production of solid oral dosage forms.
[0007] In summary, existing technologies lack a method for preparing lutein chewable tablets that can achieve efficient solubilization of lutein, ensure a complete dissolution profile, and effectively suppress dissolution behavior drift during storage. How to improve the formulation and manufacturing process to achieve uniform dispersion of lutein and the solubilizing carrier at the molecular level, ensuring that the dissolution profile of the chewable tablets remains unchanged during storage, while also guaranteeing the stability of related substances in the product during storage, is a pressing technical problem to be solved in this field. Summary of the Invention
[0008] In the field of ophthalmology, particularly in the development of nutritional formulations, lutein possesses significant clinical value in protecting macular pigment and providing antioxidant benefits. However, its formulation has long been constrained by two intertwined challenges: extremely low water solubility, making effective release from solid dosage forms difficult; and poor chemical stability, making it sensitive to light, heat, and oxygen, and prone to oxidative degradation and isomerization. Existing technologies often improve lutein's water solubility through solubilization, but after solubilization, lutein is dispersed in molecular or amorphous forms, making it more susceptible to the effects of oxygen, light, and heat than in its crystalline state, resulting in even worse stability. Therefore, achieving both solubility and stability is difficult.
[0009] Based on this, a process approach that simultaneously achieves "solubilization-stabilization-forming" is proposed: using a compound of oryzanol and poloxamer 188 as a composite carrier system, lutein, oryzanol, and poloxamer 188 are dissolved together in anhydrous ethanol or 95% ethanol to form a homogeneous drug-containing spray solution; fillers and flavoring agents are then spray-granulated in a fluidized bed in a one-step process. The ferulic acid ester skeleton of oryzanol can form an antioxidant protective microenvironment around lutein molecules, while the polyoxyethylene segments of poloxamer 188 provide hydrophilic release channels. The two form a composite carrier in the spray solution through hydrogen bonding, which helps to disperse lutein in a molecular state; the one-step fluidized bed granulation allows the solvent to evaporate simultaneously during particle formation, eliminating the need for secondary granulation and drying of lutein as required by traditional solid dispersion methods.
[0010] Further investigation revealed that synergistic control of particle size distribution, moisture content, and tablet hardness in the total mixed intermediate product significantly improved the optimal tablet appearance, release behavior, and storage stability of chewable tablets. Specifically, when the proportion of 60-80 mesh particles in the total mixed intermediate product was controlled at 60-90%, the loss on drying was 2.0%-3.5%, the tablet hardness was 8-15 kg, and the main compression pressure was 50-70 kN, the resulting chewable tablets achieved a lutein dissolution rate ≥90% after 45 minutes. Furthermore, after 6 months of accelerated storage, the lutein dissolution rate remained essentially unchanged, achieving integrated solubilization, stabilization, and tablet formation.
[0011] This invention is achieved through the following means: In a first aspect, the present invention provides a method for preparing ophthalmic lutein chewable tablets, which comprises the following steps: S1, Solution preparation: Add the prescribed amounts of lutein, oryzanol, and poloxamer 188 to an organic solvent, stir to dissolve, and obtain a medicated spray solution. S2, Granulation: Fillers and flavoring agents are placed in a fluidized bed granulator, and the drug-containing spray liquid is sprayed in the fluidized state for one-step fluidized bed granulation to obtain drug-containing granules; the drug-containing granules are then mixed evenly with flavoring and lubricant to obtain total mixed intermediate granules. S3, tableting: Based on the total particle content of the intermediate products, tablets are compressed to obtain lutein chewable tablets. Furthermore, the organic solvent is selected as anhydrous ethanol or 95% ethanol. As a preferred solvent, ethanol is a Class III solvent as defined in the Chinese Pharmacopoeia and ICH Q3C guidelines, with low toxicity and high safety. Moreover, lutein and poloxamer 188 both have good solubility in ethanol, which is beneficial for forming a uniform drug-containing spray.
[0012] Furthermore, the granulation parameters for the first step are: inlet air temperature 50-80℃, inlet air frequency 15-35HZ, spray speed 5-20ml / min, atomization pressure 0.1-0.4Mpa, and nozzle inner diameter 0.8-1.5mm. The most preferred parameters are: inlet air temperature 65℃, inlet air frequency 25HZ, spray speed 10ml / min, atomization pressure 0.25Mpa, and nozzle inner diameter 1.2mm; these parameters can achieve the target intermediate particle size and the most suitable drying loss for the technical solution of this invention.
[0013] Using the granulation parameters provided above, in the granulation process, the weight percentage of particles with a particle size of 60-80 mesh in the powder composition of the total mixed intermediate product particles can be 60-90%, and the drying loss can be 2.0-3.5%.
[0014] Furthermore, the main compression pressure is controlled at 50-70 kN. Through the synergistic control of particle size distribution, moisture content, and main tablet pressure of the total mixed intermediate particles, a finished product with a tablet hardness of 8-15 kg can be obtained. According to the compression parameters provided by this invention, the obtained finished product not only has a smooth and flat surface and neat edges, but also exhibits near-complete dissolution, with minimal decrease in dissolution during long-term storage, thus achieving excellent long-term stability.
[0015] Secondly, the present invention provides a lutein chewable tablet prepared by the above method, wherein the lutein chewable tablet is composed of the following components in parts by weight: Lutein 0.5-1.5 parts Oryzanol 0.3-3 parts Polosham 188 1.5-8 servings 80-95 parts of filler 2-6 parts of flavoring agent Fragrance 0.1-0.5 parts 0.5-2 parts of lubricant.
[0016] Furthermore, the amount of oryzanol, by weight, is 0.5-1.5 times that of lutein; the amount of poloxamer 188, by weight, is 3-5 times that of lutein. Preferably, the amount of oryzanol, by weight, is the same as that of lutein; and the amount of poloxamer 188, by weight, is 4 times that of lutein.
[0017] Furthermore, the filler is one or more of mannitol, sorbitol, xylitol, microcrystalline cellulose, pregelatinized starch, and maltitol.
[0018] Furthermore, the flavoring agent is one or more of the following: steviol glycosides, sucralose, aspartame, sodium saccharin, citric acid, and malic acid.
[0019] Furthermore, the flavoring is one or more of sweet orange flavoring, lemon flavoring, peppermint flavoring, and blueberry flavoring; the lubricant is one or more of magnesium stearate, calcium stearate, talc, and polyethylene glycol 6000.
[0020] As the most preferred embodiment of the lutein chewable tablet provided by the present invention, the lutein chewable tablet is composed of the following components in parts by weight: 1 part lutein 1 serving of oryzanol Polosham 188 4 copies 80 parts xylitol 10 parts microcrystalline cellulose 3 parts of steviol glycosides 1 part citric acid 0.3 parts sweet orange flavoring 1 part magnesium stearate.
[0021] The beneficial effects of this invention compared to the prior art are as follows: 1. Simultaneously solved the problems of lutein solubilization and stability. In existing technologies, while solubilization methods such as solid dispersions and microencapsulation can improve the solubility of lutein, the lutein dispersed in molecular or amorphous form after solubilization is more susceptible to the effects of oxygen, light, and heat than in the crystalline state, resulting in decreased stability. This invention forms a composite carrier system by combining oryzanol and poloxamer 188. The ferulic acid ester skeleton of oryzanol forms an antioxidant protective microenvironment around the lutein molecules, while the polyoxyethylene segments of poloxamer 188 provide hydrophilic release channels. The synergistic effect of the two enables lutein to maintain storage stability while achieving high solubility, achieving a synergistic gain effect that cannot be achieved by a single solubilizing carrier or simple physical mixing.
[0022] 2. The active ingredient lutein in the chewable tablets has a high solubility and does not decrease during storage. This invention achieves good dissolution by selecting the formulation (such as the proportion of active ingredients in the whole) and designing the process to co-dissolve lutein, oryzanol, and poloxamer 188 in the spray liquid in a molecular state. This allows lutein to be dispersed in the composite carrier in a molecular state during the granulation process, thus achieving rapid drug release.
[0023] By controlling the mixing of intermediate product granules and powders, drying loss, or tableting processes, the internal pore structure of tablets and the state of the drug can be kept stable during storage.
[0024] 3. Fewer process steps, one-step granulation achieves integrated "solventization-stabilization-molding". This invention employs a fluidized bed one-step granulation technology, which directly sprays the drug-containing spray liquid into a fluidized bed of fillers and flavoring agents. Solvent evaporation, lutein molecular-level dispersion, and granulation are completed simultaneously in a single process. There is no need to prepare solid dispersion powder first, avoiding the damage to the solubilized structure caused by secondary granulation and drying. This significantly shortens the process chain and reduces production costs.
[0025] 4. The product has a good taste and high patient compliance. The lutein chewable tablets obtained by this invention, through a reasonable ratio of flavoring agents and fragrances, mask the unpleasant odors of lutein and oryzanol, resulting in a pleasant taste. Furthermore, the particles obtained by this invention through one-step fluidized bed granulation have a concentrated particle size distribution, good flowability, minimal weight variation during tablet compression, and moderate tablet hardness. They are also free of gritty texture during chewing, leading to high patient compliance and making them particularly suitable for long-term use as ophthalmic nutritional supplements. Attached Figure Description
[0026] Figure 1 This is a flowchart illustrating the preparation process of the lutein chewable tablets of the present invention. Figure 2 The appearance of the tablet in Example 1 of Test Example 1; Figure 3 The appearance of the tablets in Comparative Example 3 of Experimental Example 1; Figure 4 For the accelerated 6-month chromatogram of relevant substances in Example 1 of Experiment 3; Figure 5 The image shows the relevant material spectra of Comparative Example 1 in Experiment 3 after 6 months of accelerated reaction. Detailed Implementation
[0027] The following examples of lutein chewable tablets further illustrate the present invention. These examples are merely illustrative of the formulation and process of the present invention and do not limit the scope of protection of the present invention. Conventional adjustments to the raw material ratios, granulation parameters, or tableting parameters made within the scope of the present invention are still within the scope of protection of the present invention.
[0028] Technical terms not otherwise defined in this specification have the same meaning as commonly used in the art. Operations not specified under specific conditions in the examples should be performed according to conventional methods or equipment supplier recommendations in the art; raw materials and excipients not specifying their source are all commercially available pharmaceutical-grade raw material products. Unless otherwise stated, all parts, proportions, and percentages mentioned herein are by weight.
[0029] Example 1: Preparation of Lutein Chewable Tablets formula: like Figure 1 As shown, the preparation process is as follows: S1, Solution preparation: The prescribed amounts of lutein, oryzanol, and poloxamer 188 were added to 400g of 95% ethanol and stirred for 30min at 25±5℃ and 200r / min to obtain a medicated spray solution for later use. The total solid content of lutein, oryzanol, and poloxamer 188 in the medicated spray solution was approximately 13% (g / g).
[0030] S2, Granulation: The filler and flavoring agent are placed in an explosion-proof fluidized bed granulator. The blower is turned on, and the inlet air temperature is set to 65℃ and the inlet air frequency to 25Hz, so that the material is fluidized and preheated to 40-45℃. Then, the above-mentioned drug-containing spray solution is sprayed in for one-step fluidized bed granulation. The spraying speed is 12.5ml / min, the atomization pressure is 0.25MPa, and the nozzle inner diameter is 1.2mm. During the spraying process, the material temperature is controlled at 40-50℃. After spraying, fluidized bed drying continues until the particle drying loss is 2.8%. Drug-containing granules are obtained.
[0031] The above-mentioned drug-containing granules, sweet orange flavoring, and magnesium stearate were added to a three-dimensional mixer and mixed at 15 r / min for 10 min until homogeneous, thus obtaining the total mixed intermediate granules.
[0032] S3, tableting: Take the total mixed intermediate product granules and determine the lutein content. Calculate the tablet weight based on the measured content, ensuring each tablet contains approximately 10 mg of lutein. Use a rotary tablet press, controlling the main compression pressure at 60 kN and the compression speed at 15-20 r / min, to compress the tablets and obtain lutein chewable tablets.
[0033] Example 2: Preparation of Lutein Chewable Tablets formula: Preparation process: S1, Solution preparation: Add the prescribed amounts of lutein, oryzanol, and poloxamer 188 to 400g of 95% ethanol, and stir for 30min at 25±5℃ and 200r / min to obtain a medicated spray solution for later use.
[0034] S2, Granulation: The filler and flavoring agent were placed in an explosion-proof fluidized bed granulator. The blower was turned on, and the inlet air temperature was set to 80℃ and the inlet air frequency to 15Hz, so that the material was fluidized and preheated to 50℃. Then, the above-mentioned drug-containing spray solution was sprayed in for one-step fluidized bed granulation. The spraying speed was 5ml / min, the atomization pressure was 0.15MPa, and the nozzle inner diameter was 0.8mm. During the spraying process, the material temperature was controlled at 40-50℃. After spraying, fluidized bed drying continued until the particle drying loss was 2.2%. Drug-containing granules were obtained.
[0035] The above-mentioned drug-containing granules, sweet orange flavoring, and magnesium stearate were added to a three-dimensional mixer and mixed at 15 r / min for 10 min until homogeneous, thus obtaining the total mixed intermediate granules.
[0036] S3, tableting: Take the total mixed intermediate product granules and determine their lutein content. Calculate the tablet weight based on the measured content, ensuring each tablet contains approximately 15 mg of lutein. Use a rotary tablet press, controlling the main compression pressure at 50 kN and the compression speed at 10 r / min, to compress the tablets and obtain lutein chewable tablets.
[0037] Example 3: Preparation of Lutein Chewable Tablets formula: Preparation process: S1, Solution preparation: Add the prescribed amounts of lutein, oryzanol, and poloxamer 188 to 400g of anhydrous ethanol, and stir for 30min at 25±5℃ and 200r / min to obtain a medicated spray solution for later use.
[0038] S2, Granulation: The filler and flavoring agent were placed in an explosion-proof fluidized bed granulator. The blower was turned on, and the inlet air temperature was set to 55℃ and the inlet air frequency to 30Hz, so that the material was fluidized and preheated to 55℃. Then, the above-mentioned drug-containing spray solution was sprayed in for one-step fluidized bed granulation. The spraying speed was 20ml / min, the atomization pressure was 0.4MPa, and the nozzle inner diameter was 1.5mm. During the spraying process, the material temperature was controlled at 40-45℃. After spraying, fluidized bed drying continued until the particle drying loss was 3.4%. Drug-containing granules were obtained.
[0039] The above-mentioned drug-containing granules, sweet orange flavoring, and magnesium stearate were added to a three-dimensional mixer and mixed at 15 r / min for 10 min until homogeneous, thus obtaining the total mixed intermediate granules.
[0040] S3, tableting: Take the total mixed intermediate product granules, determine the lutein content, and calculate the tablet weight based on the measured content, so that each tablet contains approximately 10 mg of lutein. Use a rotary tablet press, control the main compression pressure at 70 kN and the compression speed at 25 r / min, and compress to obtain lutein chewable tablets.
[0041] Example 4: Preparation of lutein chewable tablets with different amounts of oryzanol and poloxamer formula: Preparation process: Same as in Example 1.
[0042] Comparative Example 1: Preparation of Lutein Chewable Tablets Using a Non-soluble Method (containing Lutein and Vitamin B1) formula: Same as in Example 1.
[0043] Preparation process: To fully compare the beneficial effects of lutein, oryzanol, and poloxamer 188 dissolved in organic solvents as binders in the preparation of drug-containing sprays, this comparative example was designed. Lutein and oryzanol were initially mixed in solid powder form and then added to a fluidized bed. Granulation was then performed in one step using an ethanol solution containing poloxamer 188. Specific preparation process parameters are as follows: S1, Solution preparation: Add the prescribed amount of poloxamer 188 to 400g of 95% ethanol and stir for 30min at 25±5℃ and 200r / min to obtain a spray solution for later use. S2, Granulation: Lutein, oryzanol, fillers, and flavoring agents were placed in a three-dimensional mixer and mixed for 10 minutes at 15 r / min for initial mixing. The mixture was then placed in an explosion-proof fluidized bed granulator for one-step granulation. The subsequent preparation process and parameters (including step S3) are the same as in Example 1.
[0044] Comparative Example 2: Preparation of Lutein Chewable Tablets Using an Efficient Wet Granulation Method formula: Same as in Example 1.
[0045] Preparation process: S1, Solution preparation: Add the prescribed amounts of lutein, oryzanol, and poloxamer 188 to 150g of anhydrous ethanol, and stir for 30min at 25±5℃ and 200r / min to obtain a drug-containing adhesive paste for later use. S2 granulation: Fillers and flavoring agents are placed in a high-efficiency wet granulator and dry-mixed for 2 minutes at a stirring speed of 200 r / min and a cutting speed of 2000 r / min until homogeneous. Then, the above-mentioned medicated binder solution is added, and granulation is carried out for 3-5 minutes at a stirring speed of 200 r / min and a cutting speed of 1500 r / min to obtain a wet soft mass. The wet soft mass is then passed through a 14-mesh sieve of a gyratory granulator to produce wet granules. The wet granules are placed in a hot air circulating oven and dried at 50-60℃ until the granule drying loss is 2.8%, obtaining medicated granules. The medicated granules are then sized using an 18-mesh sieve.
[0046] The above-mentioned drug-containing granules, sweet orange flavoring, and magnesium stearate were added to a three-dimensional mixer and mixed at 15 r / min for 10 min until homogeneous, thus obtaining the total mixed intermediate granules.
[0047] S3, tableting: Consistent with Example 1, lutein chewable tablets were obtained.
[0048] Comparative Example 3: Preparation of Lutein Chewable Tablets by Dry Granulation formula: Same as in Example 1.
[0049] Preparation process: S1, Premixed: The prescribed amounts of lutein, oryzanol, poloxamer 188, xylitol, microcrystalline cellulose, steviol glycosides, and citric acid were added to a three-dimensional mixer and mixed at 15 r / min for 15 min until homogeneous, yielding a premixed material. No organic solvents were used in this step; lutein, oryzanol, and poloxamer 188 were all mixed in solid powder form.
[0050] S2, Dry Granulation The premixed materials are added to a dry granulator, and the roller pressure is set to 3-5 MPa, the roller speed to 5-10 r / min, and the tablet thickness to 0.8-1.2 mm for dry granulation. The resulting strips are then crushed and granulated, and passed through a 16-20 mesh sieve to obtain medicated granules.
[0051] The above-mentioned drug-containing granules, sweet orange flavoring, and magnesium stearate were added to a three-dimensional mixer and mixed at 15 r / min for 10 min until homogeneous, thus obtaining the total mixed intermediate granules.
[0052] S3, tableting: Consistent with Example 1, lutein chewable tablets were obtained.
[0053] Comparative Example 4: Preparation of Lutein Chewable Tablets Without Oryzanol formula: Preparation process: In this comparative example, except that oryzanol, which is not present in the formula, is no longer added in the corresponding process steps, everything else is the same as in Example 1.
[0054] Test Example 1: Hardness Test of Intermediate Powder and Flakes To fully investigate the underlying reasons and differences in the effects of the technical solutions of this invention, this experimental example examines the powder composition and hardness of the total mixed intermediate particles and tablets obtained from the examples and comparative examples, in order to evaluate the influence of different preparation processes on the quality of the intermediate particles and tableting performance. The test items include particle size distribution, loss on drying, and tablet hardness, and the methods are performed in accordance with the relevant provisions of the General Chapters, Part IV of the Chinese Pharmacopoeia.
[0055] Particle size distribution: Take an appropriate amount of intermediate particles from the total mixture and pass them through 60-mesh and 80-mesh standard sieves in sequence. Weigh the material between the 60-80 mesh sieve and calculate its weight percentage relative to the total intermediate particles.
[0056] Loss on drying: Take about 5 g of the total mixed intermediate product granules, place them in a fully automatic infrared rapid moisture analyzer, and record the data.
[0057] Tablet hardness: Take each sample tablet and measure it using a tablet hardness tester. Randomly select 10 tablets and record the hardness range and average value.
[0058] Test results: in conclusion: Examples 1-4 employed fluidized bed one-step granulation, resulting in concentrated particle size distribution, suitable drying loss, moderate tablet hardness, and uniform color and smooth surface of the unprocessed tablets. Comparative Example 4, although lacking oryzanol, had an initial appearance consistent with Example 1. Furthermore, considering the comparative examples, although the particle size, drying loss, and tablet hardness of the total mixed intermediates were appropriately controlled, differences in the appearance of the resulting tablets were observed.
[0059] For a specific photograph of the tablet's appearance, please refer to the attached diagram in the instruction manual for Example 1. Figure 2 Comparative Example 3 is shown in the attached diagram of the instruction manual. Figure 3 .
[0060] Experimental Example 2: Dissolution Determination Lutein has extremely low water solubility, and its dissolution behavior in pharmaceutical preparations directly affects the effective release and absorption of the active ingredient. After chewing tablets, lutein needs to dissolve in the gastrointestinal tract to be absorbed and utilized. Insufficient dissolution will lead to reduced bioavailability, making it difficult to achieve the expected nutritional supplementation effect. The internal pore structure and drug state of tablets obtained through different preparation processes may vary, thus affecting the release rate and extent of lutein. Therefore, to demonstrate the technical effectiveness of this invention, the dissolution rate of lutein chewable tablets obtained in representative examples and comparative examples was investigated according to the Dissolution and Release Determination Method in General Chapter 0931 of the Chinese Pharmacopoeia, Part IV.
[0061] Dissolution test: 900 ml of phosphate buffer (pH 6.8) containing 0.5% sodium dodecyl sulfate was used as the dissolution medium. The rotation speed was 50 r / min, and the temperature was 37±0.5℃. 5 ml samples were taken at 30 and 45 min, and an equal volume of isothermal dissolution medium was added simultaneously. The samples were filtered, and the filtrate was collected. The lutein content was determined by high-performance liquid chromatography (HPLC), and the cumulative dissolution rate was calculated. Twelve tablets were tested per batch, and the average value was taken.
[0062] High-performance liquid chromatography (the method for detecting lutein content in total mixed intermediate particles is consistent with that used in the examples and comparative examples): Column: Ultimate XB-C30 (5μm, 4.6×250mm) Mobile phases: Phase A is an 88% aqueous solution of 0.1% BHT in methanol; Phase B is 0.1% BHT in methyl tert-butyl ether. Flow rate: 1.0 mL / min Column temperature: 30℃ Detection wavelength: 445nm Measurement results: in conclusion: Examples 1-4 showed high initial dissolution rates, which remained stable after 6 months of accelerated dissolution, with Examples 1-3 showing a decrease of less than 5%. Comparative Examples 1, 2, and 3 had significantly lower dissolution rates due to non-co-dissolution or differences in granulation methods. Comparative Example 4, which did not contain oryzanol, had an initial dissolution rate comparable to Example 1, but its dissolution rate decreased significantly after 6 months of accelerated dissolution; this indicates that while poloxamer 188 alone, in formulations without oryzanol, can improve initial dissolution rates, it cannot maintain the stability of dissolution rates during storage.
[0063] Test Example 3: Determination of Related Substances Lutein molecules contain multiple conjugated double bonds, making them sensitive to light, heat, and oxygen. During formulation preparation and storage, they are prone to degradation reactions such as oxidation and isomerization, generating lutein cis isomers, oxidation products, and other related substances. These related substances not only affect the accuracy of lutein content in chewable tablets but may also impact product safety and stability. To evaluate the impurity profile and stability of the lutein chewable tablets prepared according to the present invention, related substances were determined on the lutein chewable tablets obtained in the examples and comparative examples, referring to the high-performance liquid chromatography method in General Chapter 0512 of the Chinese Pharmacopoeia and the guiding principles for drug impurity analysis in General Chapter 9101. The changes in related substances were observed after 6 months of accelerated storage of representative examples or comparative samples.
[0064] The relevant methods for detecting the substances are performed according to USP 35 Lutein Preparation: Detector: Ultraviolet-visible detector, detection wavelength 446 nm; Chromatographic column: 4.6 mm × 25 cm, packed with 3 μm L3 packing material (cyano-bonded silica column, such as Spherisorb CN column); Mobile phase: n-hexane-ethyl acetate (75:25, v / v), filtered and degassed before use; Flow rate: 1.5 mL / min; Injection volume: 10 μL; Column temperature: 25℃; Quantitative method: Peak area normalization method; Reference solution: Accurately weigh an appropriate amount of lutein reference standard, dissolve and dilute it in the mobile phase to prepare a solution containing approximately 150 μg of lutein per 1 mL.
[0065] Test solution: Accurately weigh an appropriate amount of lutein preparation (approximately equivalent to 5 mg of lutein), place it in a 50 mL brown volumetric flask, add an appropriate amount of solvent, sonicate (30℃, 2-5 min) to dissolve, cool, dilute to the mark with solvent, shake well, centrifuge or filter through a 0.45 μm filter membrane, and use the filtrate as the test solution. All procedures should be performed in the dark, and the solution should be freshly prepared before use.
[0066] Measurement results: in conclusion: Examples 1-4 initially showed low levels of related substances, with a slight increase after 6 months (all meeting USP requirements for related substances in lutein preparations), indicating good stability. Comparative Examples 1, 2, and 3 showed significantly increased related substances due to dispersion or process defects. Comparative Example 4, which did not contain oryzanol, had slightly higher related substances at day 0 than Example 1, but a sharp increase in total impurities after 6 months of accelerated processing. This indicates that the addition of oryzanol, forming a complex carrier with poloxamer 188, creates an antioxidant protective microenvironment around the lutein molecules, resulting in an unexpected stability-enhancing effect, allowing the lutein preparation to maintain storage stability even at high dissolution rates.
[0067] Typical spectra of related substances in Example 1 after 6 months of accelerated metabolism are shown in the attached figures of the instruction manual. Figure 4 Comparative Example 1: Typical spectra of relevant substances accelerated in June are shown in the attached figures in the instruction manual. Figure 5 .
[0068] In summary, this invention effectively overcomes the technical bottleneck of balancing solubilization and stability of lutein, achieving significant progress in powder properties, tableting performance, dissolution behavior, and chemical stability. It has significant industrial application value and provides a new path for lutein chewable tablets that is simple in process, stable in quality, and suitable for industrial production.
Claims
1. A method for preparing ophthalmic lutein chewable tablets, characterized in that, It consists of the following steps: S1, Solution preparation: Add the prescribed amounts of lutein, oryzanol, and poloxamer 188 to an organic solvent, stir to dissolve, and obtain a medicated spray solution. S2, Granulation: Fillers and flavoring agents are placed in a fluidized bed granulator, and the drug-containing spray liquid is sprayed in the fluidized state for one-step fluidized bed granulation to obtain drug-containing granules; the drug-containing granules are then mixed evenly with flavoring and lubricant to obtain total mixed intermediate granules. S3, tableting: Lutein chewable tablets are obtained by compressing the tablets according to the total content of intermediate particles.
2. The method for preparing lutein chewable tablets according to claim 1, characterized in that, The organic solvent is anhydrous ethanol or 95% ethanol.
3. The method for preparing lutein chewable tablets according to claim 1, characterized in that, The parameters for the one-step granulation are as follows: air inlet temperature 50-80℃, air inlet frequency 15-35HZ, spray speed 5-20ml / min, atomization pressure 0.1-0.4Mpa, and nozzle inner diameter 0.8-1.5mm.
4. The method for preparing lutein chewable tablets according to claim 1, characterized in that, In the granulation process, the weight percentage of particles with a particle size of 60-80 mesh in the total mixed intermediate particles is controlled to be 60-90%, and the loss on drying is controlled to be 2.0-3.5%; in the tableting process, the tablet hardness is controlled to be 8-15 kg; and the main tableting pressure is controlled to be 50-70 kN.
5. A lutein chewable tablet prepared by the method described in claim 1, characterized in that, The lutein chewable tablets, by weight, consist of the following components: Lutein 0.5-1.5 parts Oryzanol 0.3-3 parts Polosham 188 1.5-8 servings 80-95 parts of filler 2-6 parts of flavoring agent Fragrance 0.1-0.5 parts 0.5-2 parts of lubricant.
6. The lutein chewable tablet according to claim 5, characterized in that, The amount of oryzanol, by weight, is 0.5-1.5 times that of lutein; the amount of poloxamer 188, by weight, is 3-5 times that of lutein.
7. The lutein chewable tablet according to claim 5, characterized in that, The filler is one or more of mannitol, sorbitol, xylitol, microcrystalline cellulose, pregelatinized starch, and maltitol.
8. The lutein chewable tablet according to claim 5, characterized in that, The flavoring agent is one or more of the following: steviol glycosides, sucralose, aspartame, sodium saccharin, citric acid, and malic acid.
9. The lutein chewable tablet according to claim 5, characterized in that, The flavoring is one or more of sweet orange flavoring, lemon flavoring, peppermint flavoring, and blueberry flavoring; the lubricant is one or more of magnesium stearate, calcium stearate, talc, and polyethylene glycol 6000.
10. The lutein chewable tablet according to claim 5, characterized in that, The lutein chewable tablets, by weight, consist of the following components: 1 part lutein 1 serving of oryzanol Polosham 188 4 copies 80 parts xylitol 10 parts microcrystalline cellulose 3 parts of steviol glycosides 1 part citric acid 0.3 parts sweet orange flavoring 1 part magnesium stearate.
Citation Information
Patent Citations
Xanthophyll chewable tablet
CN103083270B
Functional lutein chewable tablet and preparation method thereof
CN117016785A
